Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M

MARAVAI LIFESCIENCES HOLDINGS, INC.

2025-Q1 EPS reported -$0.21 revenue$46,850,000

Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.
Adjusted EBITDA fell to $(10.5)M from $7.8M in prior-year quarter.
Nucleic Acid Production revenue $28.8M (-37.5% YoY) on lack of high-volume CleanCap orders; Biologics Safety Testing $18.1M (flat YoY).
Full-year 2025 revenue guidance maintained at $185M-$205M, excluding potential high-volume CleanCap vaccine orders.
Base business (ex CleanCap vaccine) grew >$4M sequentially from Q4 2024, per CEO Trey Martin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.